The crude incidence of Hodgkin lymphoma (HL) in the European Union is 2.3, the mortality
0.4 cases/100000/year. Young adults aged 20–40 years are most often affected. Slightly …

Hodgkin lymphoma (HL), a B cell–derived cancer, is one of the most common lymphomas. In
HL, the tumor cells—Hodgkin and Reed-Sternberg (HRS) cells—are usually very rare in the …

Background Whether it is possible to reduce the intensity of treatment in early (stage I or II)
Hodgkin's lymphoma with a favorable prognosis remains unclear. We therefore conducted a …

PURPOSE Combined-modality treatment (CMT) with 2× ABVD (doxorubicin, bleomycin,
vinblastine, and dacarbazine) and small-field radiotherapy is standard of care for patients …

Background Chemotherapy plus radiation treatment is effective in controlling stage IA or IIA
nonbulky Hodgkin's lymphoma in 90% of patients but is associated with late treatment …

The crude incidence of Hodgkin's lymphoma (HL) in the European Union is 2.3 and the
mortality is 0.4 cases/100 000/year. Young adults aged 20–40 years are most often affected; …

Background Treatment of early-stage Hodgkin's disease is usually tailored in line with
prognostic factors that allow for reductions in the amount of chemotherapy and extent of …

Background The role of bleomycin and dacarbazine in the ABVD regimen (ie, doxorubicin,
bleomycin, vinblastine, and dacarbazine) has been questioned, especially for treatment of …

Management of Hodgkin's lymphoma continues to develop. Outcomes for patients with
favourable-risk, early-stage disease are excellent, and serial reductions in intensity of …

Purpose Combined-modality treatment is widely considered the standard of care in early-
stage Hodgkin lymphoma (HL), and treatment intensity has been reduced over the last …